Vietnam is emerging as one of Southeast Asia's most promising growth markets for GLP-1 receptor agonists, as rising rates of diabetes, obesity, and metabolic disorders drive demand for next-generation therapies.
Industry estimates suggest that Vietnam's GLP-1 market could grow at an annual rate of 22% through 2030, making it one of the fastest-growing pharmaceutical segments in the country. Increasing awareness of obesity as a chronic disease, alongside growing adoption of advanced treatments such as semaglutide and tirzepatide, is transforming the metabolic health landscape.
The growth comes against the backdrop of a rapidly expanding diabetes market. Vietnam's diabetes drugs market is forecast to grow to more than US$625 million by 2034, with GLP-1 therapies expected to capture an increasing share of treatment spending due to their proven benefits in glycaemic control, weight management, and cardiovascular risk reduction.
Key drivers shaping the market include:
- Rising prevalence of type 2 diabetes and obesity
- Growing availability of innovative therapies including Ozempic, Wegovy, Rybelsus, Mounjaro, and Trulicity
- Increasing physician and patient awareness of metabolic health management
- Expansion of private healthcare services and specialist obesity clinics
- Growing investment in preventive healthcare and chronic disease management
Globally, GLP-1 receptor agonists have become one of the most valuable pharmaceutical categories in history, with worldwide market revenues expected to exceed US$170 billion by 2033. As access improves and healthcare systems focus increasingly on chronic disease prevention, Vietnam is well positioned to become a key growth market within the ASEAN region.
For pharmaceutical companies, healthcare providers, investors, and policymakers, the rapid rise of GLP-1 therapies signals a significant shift in the future of diabetes and obesity management across Southeast Asia.
